A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate The Efficacy, Safety And Tolerability Of 2 Doses Of Oral Administration Of Laquinimod (0.6 mg/Day Or 1.2 mg/Day) Compared to Interferon ß-1a Administered Intra Muscular Once Weekly in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).

Trial Profile

A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate The Efficacy, Safety And Tolerability Of 2 Doses Of Oral Administration Of Laquinimod (0.6 mg/Day Or 1.2 mg/Day) Compared to Interferon ß-1a Administered Intra Muscular Once Weekly in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Laquinimod (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms LIBRETTO
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 23 Mar 2017 This trial has been Discontinued in UK (global end date-19-2-2014), according to European Clinical Trials Database.
    • 03 Mar 2014 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 19 Feb 2014 The trial will not proceed to the randomisation stage as decided by Teva Pharmaceuticals, as reported in a partner media release issued by Active Biotech. The trial design is no longer aligned with the regulatory strategy. Other trials are not impacted.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top